Effects of Salvianolic Acid B/ginsenoside Rg1 Combination Against Chronic Pulmonary Embolism Induced by Polystyrene Microspheres

Pulmonary embolism (PE) is the most life-threatening complication of venous thromboembolism, but few effective treatments have been discovered to attenuate chronic PE currently. In this study, we investigated the protective effects of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1) combination (SalB/Rg1) on chronic PE and explored the potential mechanisms. The PE model was induced by 45 μm polystyrene microspheres and 20 mg/kg of SalB/Rg1 was administered to PE rats intraperitoneally. A histopathological analysis of the lungs and heart was performed through hematoxylin and eosin staining and immunohistochemical analysis. The pulmonary index and right ventricular cardiomyocyte cross-sectional area were evaluated. SalB/Rg1 markedly downregulated pulmonary index, attenuated pulmonary interstitial changes, suppressed neutrophil infiltration, prevented collagen deposition, and inhibited MMP-9 activities in the lung. We also found that SalB/Rg1 improved right ventricular hypertrophy accompanied by reducing the cardiomyocyte cross-sectional area. These data suggest that SalB/Rg1 played a protective role against microsphere-induced PE and holds a high potential for the treatment of PE in the future.

[1]  C. Baggio,et al.  Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease. , 2020, Journal of medicinal chemistry.

[2]  J. Rasgon,et al.  Clotting disorder in severe acute respiratory syndrome coronavirus 2 , 2020, Reviews in medical virology.

[3]  Sonali Gupta,et al.  Prevalence and Clinical Impact of Atrial Fibrillation in Patients with Pulmonary Embolism. , 2020, Southern medical journal (Birmingham, Ala. Print).

[4]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) , 2019, European Respiratory Journal.

[5]  D. Duncker,et al.  Cardiac remodelling in a swine model of chronic thromboembolic pulmonary hypertension: comparison of right vs. left ventricle , 2019, The Journal of physiology.

[6]  R. Sarkar,et al.  Fibrinolysis and Inflammation in Venous Thrombus Resolution , 2019, Front. Immunol..

[7]  J. Brachmann,et al.  Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. , 2019, European heart journal.

[8]  J. Kline,et al.  Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition. , 2017, The American journal of pathology.

[9]  J. D’Armiento,et al.  Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis. , 2017, American journal of physiology. Heart and circulatory physiology.

[10]  Z. Qiao,et al.  SALVIANOLIC ACID B ALLEVIATING MYOCARDIUM INJURY IN ISCHEMIA REPERFUSION RATS , 2016, African journal of traditional, complementary, and alternative medicines : AJTCAM.

[11]  G. Raskob,et al.  Global Burden of Thrombosis: Epidemiologic Aspects. , 2016, Circulation research.

[12]  Wan-ying Wu,et al.  The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice , 2015, International journal of molecular sciences.

[13]  B. Wang,et al.  Ginsenoside Rg1 improves lipopolysaccharide-induced acute lung injury by inhibiting inflammatory responses and modulating infiltration of M2 macrophages. , 2015, International immunopharmacology.

[14]  Wan-ying Wu,et al.  Combined Salvianolic Acid B and Ginsenoside Rg1 Exerts Cardioprotection against Ischemia/Reperfusion Injury in Rats , 2015, PloS one.

[15]  Wan-ying Wu,et al.  Ginsenoside Rg1 and Rb1, in combination with salvianolic acid B, play different roles in myocardial infarction in rats , 2015, Journal of the Chinese Medical Association : JCMA.

[16]  H. Magnussen,et al.  Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. , 2011, Pulmonary pharmacology & therapeutics.

[17]  Xu Shen,et al.  Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling , 2010, BMC pharmacology.

[18]  K. Sato,et al.  Involvement of Rho kinase in the pathogenesis of acute pulmonary embolism-induced polystyrene microspheres in rats. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[19]  K. Kerr,et al.  Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension , 2004, European Respiratory Journal.